The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Number of sites of metastasis (NSM) and progression-free survival (PFS) in patients (PTS) with melanoma treated with ipilimumab (IPI).
Monique Celeste Tavares
No relevant relationships to disclose
Milton Jose De Barros E. Silva
No relevant relationships to disclose
Jose A. Rinck
No relevant relationships to disclose
Ana Claudia Machado Urvanegia
No relevant relationships to disclose
Mariana Petaccia Macedo
No relevant relationships to disclose
Clovis Pinto
No relevant relationships to disclose
Tiago Bezerra
No relevant relationships to disclose
Graziela Zibetti Dal Molin
No relevant relationships to disclose
Fábio Nasser Santos
No relevant relationships to disclose
Rosely Yamamura
No relevant relationships to disclose
Geraldine Eltz Lima
No relevant relationships to disclose
Marcello Ferretti Fanelli
No relevant relationships to disclose